Esophageal cancer is one of the deadliest cancers worldwide. It typically has a poor overall prognosis because of diagnosis in advanced stages. Sensitive biomarkers for the early detection of esophageal cancer are urgently needed to reduce the high mortality of this disease. Circulating microRNAs (miRNAs) are emerging as a novel non-invasive biomarker for cancer diagnosis due to its high stability and specificity. In this study, we profiled circulating miRNAs in serum of patients with esophageal adenocarcinoma (EAC) using the Solexa sequencing analysis. The analysis demonstrated marked differences of more than 195 circulating miRNAs including 96 of upregulated and 99 of downregulated miRNA in EAC patients compared with healthy subjects. Quantitative reverse transcription PCR verified that the concentrations of circulating miR-25-3p and miR-151a-3p were significantly elevated, while the concentrations of miR-100-5p and miR-375 were significantly decreased in EAC patients compared with healthy controls. These data indicate the profile of these 4 miRNAs may potentially serve as a serum biomarker to identify patients with EAC, and circulating miRNA profiling may be clinically useful for early detection or treatment response in EAC patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5126285 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Context-dependent effects of CDKN2A and other 9p21 gene losses during the evolution of esophageal cancer.
Nat Cancer
January 2025
Cancer Systems Biology Laboratory, The Francis Crick Institute, London, UK.
CDKN2A is a tumor suppressor located in chromosome 9p21 and frequently lost in Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC). How CDKN2A and other 9p21 gene co-deletions affect EAC evolution remains understudied. We explored the effects of 9p21 loss in EACs and cancer progressor and non-progressor BEs with matched genomic, transcriptomic and clinical data.
View Article and Find Full Text PDFDistinct immune signatures for predicting the immunotherapy efficacy of esophageal squamous cell carcinoma or adenocarcinoma.
Cancer Immunol Immunother
January 2025
Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
Esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) are distinct histological subtypes of esophageal cancer. The tumor microenvironment of each subtype significantly influences the efficacy of immunotherapy. However, the characteristics of the tumor microenvironments of both subtypes, as well as their specific impacts on immunotherapy outcomes, still require further elucidation.
View Article and Find Full Text PDFNon-Hodgkin Lymphoma of the External Auditory Canal: A Rare Primary Involvement.
Cureus
December 2024
Internal Medicine Department, Unidade Local de Saúde do Nordeste, Bragança, PRT.
The authors describe a rare case of non-Hodgkin lymphoma (NHL) with primary involvement of the external auditory canal (EAC) and subsequent dissemination to the central nervous system, initially manifesting as a benign ear infection. This case highlights the importance of considering differential diagnoses in patients with persistent or worsening symptoms unresponsive to empirical treatment. A 53-year-old man presented with a one-week history of aural fullness, otalgia, and otorrhea in the left ear.
View Article and Find Full Text PDFDeciphering the Prognostic Landscape of Esophageal Adenocarcinoma: A PANoptosis-Related Gene Signature.
J Cancer
January 2025
Department of Pathology, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210000, China.
Article Synopsis
- Esophageal adenocarcinoma (EAC) has low survival rates despite treatment advancements, so understanding molecular mechanisms and identifying prognostic markers is essential for better patient outcomes.
- A bioinformatics analysis identified 8 key PANoptosis-related genes (PRGs) to create a prognostic risk score model that outperformed traditional staging methods and was validated through multiple analyses, including gene expression profiling and immune infiltration assessment.
- The study utilized techniques like WGCNA and RT-qPCR to identify crucial hub genes, whose effects on EAC cell behavior were tested in vitro, ultimately leading to a novel prognostic nomogram that integrates clinical features for improved predictive accuracy.
Clinicopathological and therapeutic comparisons of esophageal cancer between China and the USA: a multicenter hospital-based study.
J Natl Cancer Cent
December 2024
Office of National Central Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Background: Esophageal cancer (EC) remains a global health challenge due to its poor prognosis. China and the United States of America (USA) represent two distinct epicenters of EC burden. Understanding the EC disparities in these two countries is vital for tailoring prevention strategies, optimizing treatment, and enhancing outcomes in both countries.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!